| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.17 | 0.0007 |
| mRNA | selumetinib:tretinoin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0008 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0009 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.001 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |